Sun Christina, Lay Christine, Broner Susan, Silberstein Stephen, Tepper Stewart, Newman Lawrence
The Headache Institute, Roosevelt Hospital, New York, NY 10019, USA.
Headache. 2006 Oct;46(9):1450-3. doi: 10.1111/j.1526-4610.2006.00587.x.
To describe 7 patients who developed new onset anorgasmia while using topiramate therapy for migraine prophylaxis.
Topiramate is an effective drug for the prevention of migraine headaches. Though it is generally well tolerated, it may be associated with a dose-related anorgasmia.
Case reports.
Seven patients (5 women, 2 men), between the ages of 40 and 62, developed anorgasmia while using topiramate for headache prevention. Four women and 2 men had migraine without aura, and 1 woman had migraine with aura. None had a prior history of anorgasmia or sexual dysfunction. Doses associated with this side effect ranged from 45 to 200 mg daily. All subjects had symptom resolution. Six patients had resolution within 7 days of discontinuing or decreasing the medication; the exact time frame of resolution for the seventh patient is unknown.
In our series, anorgasmia was a reversible, dose-related adverse effect of topiramate. Physicians need to be aware of the potential for topiramate to cause sexual side effects, and should inquire about these symptoms in patients for whom this agent has been prescribed.
描述7例在使用托吡酯预防偏头痛治疗过程中出现新发性高潮障碍的患者。
托吡酯是预防偏头痛的一种有效药物。虽然它通常耐受性良好，但可能与剂量相关的性高潮障碍有关。
病例报告。
7例患者（5名女性，2名男性），年龄在40至62岁之间，在使用托吡酯预防头痛过程中出现性高潮障碍。4名女性和2名男性患无先兆偏头痛，1名女性患伴有先兆偏头痛。所有患者既往均无性高潮障碍或性功能障碍病史。与该副作用相关的剂量范围为每日45至200毫克。所有受试者症状均得到缓解。6例患者在停药或减药后7天内症状缓解；第7例患者症状缓解的确切时间未知。
在我们的系列研究中，性高潮障碍是托吡酯一种可逆的、与剂量相关的不良反应。医生需要意识到托吡酯可能导致性方面副作用的可能性，并且应该向使用该药物的患者询问这些症状。
